Dr. Evanthia Bernitsas, MD

Dr. Bernitsas practices at CHI Alegent Health Physical Therapy Clinic Bergan - Unit in Omaha, Nebraska.

Dr. Bernitsas' NPI, 1528270808, was assigned on May 7, 2007. Dr. Bernitsas graduated from Aristotle University of Thessaloniki School of Medicine in 1989. Dr. Bernitsas' Michigan license number on file is 4301095490.

Dr. Bernitsas' primary practice is CHI Alegent Health Physical Therapy Clinic Bergan - Unit, at 7710 Mercy Rd, Omaha, NE 68124.

Dr. Bernitsas' primary practice is CHI Alegent Health Physical Therapy Clinic Bergan - Unit in Omaha, Nebraska. Dr. Bernitsas is also affiliated with CHI Health Creighton University Medical Center - Bergan Mercy. The medical group on file is CHI Health Clinic. Dmand AI also links Dr. Bernitsas to 3 more hospitals, 1 group practice or clinic, 1 hospital outpatient department and 1 medical group, each named with a free account. Dr. Bernitsas' employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Bernitsas practices, 7 sites in all. Vendor and product names are available with a free account.

Neurology is Dr. Bernitsas' primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dr. Bernitsas is board certified in neurology by the American Board of Psychiatry and Neurology. Dmand AI has Dr. Bernitsas' licenses on file in 3 states: Michigan, Nebraska and Ohio.

Dmand AI lists acute mini-stroke (TIA), encephalopathy, lower back pain, multiple sclerosis and stroke among the conditions Dr. Bernitsas treats.

CMS data shows 44 Medicare services from Dr. Bernitsas across 1 procedure code in 2024, all of them office visits, for 53 Medicare patients. Medicare paid $2,799 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 53 Medicare patients who saw Dr. Bernitsas in 2024. The largest group is under 65, with 27 patients. 70% of them have high blood pressure, and 57% have arthritis. 55% are also on Medicaid. Their average risk score is 1.59, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Bernitsas' median patient age at 59, with 65% women.

In 2024, Dr. Bernitsas wrote 964 Medicare Part D claims for 129 patients. 73% of them were for generic drugs. CMS names the drug for 765 of them, across 25 drugs with 11 or more claims each, at $2,124,372 in total drug cost. In 2023, CMS named 1,413 claims across 38 drugs.

Dr. Bernitsas accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 43 papers to Dr. Bernitsas, published from 2014 to 2025. 2018 was the busiest year, with 5. The most frequent topics are Multiple Sclerosis, Magnetic Resonance Imaging and Multiple Sclerosis, Relapsing-Remitting. Dr. Bernitsas has published most often in Mult Scler Relat Disord. Dr. Bernitsas' most frequent co-authors are Shitiz Kumar Sriwastava, MD, Michael Joel Brenner, MD and Navid Seraji-Bozorgzad, MD.

Dmand AI links Dr. Bernitsas to 2 clinical trials. Conditions studied include Multiple Sclerosis, Multiple Sclerosis, Chronic Progressive and Demyelinating Autoimmune Diseases, CNS.

CMS Open Payments shows 528 general payments to Dr. Bernitsas from 18 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 60% of the total. Biogen, Inc. paid the most, $205,238. It also lists 15 research payments totaling $11,201 from 2017 to 2025.

Dr. Bernitsas graduated from Aristotle University of Thessaloniki School of Medicine in 1989. Dr. Bernitsas is a member of AAN.

Dr. Bernitsas is in network with 16 carriers, including Elevance, United Healthcare and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.